Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

Authors

Désirée van der Heijde
Atul Deodhar
Oliver FitzGerald
Roy Fleischmann
Dafna Gladman
Alice B Gottlieb
Bengt Hoepken
Lars Bauer
Oscar Irvin-Sellers
Majed Khraishi
Luke Peterson
Anthony Turkiewicz
Jürgen Wollenhaupt
Philip Mease, Swedish Medical Center and University of Washington, Seattle, Washington, USA.Follow

Document Type

Article

Publication Date

3-26-2018

Publication Title

RMD Open

Keywords

anti-tnf; dmards (biologic); psoriatic arthritis; tnf-alpha

Abstract

[This corrects the article DOI: 10.1136/rmdopen-2017-000582.][This corrects the article DOI: 10.1136/rmdopen-2017-000582.].

Clinical Institute

Orthopedics & Sports Medicine

Department

Orthopedics

Department

Rheumatology

Recommended Citation

van der Heijde, Désirée; Deodhar, Atul; FitzGerald, Oliver; Fleischmann, Roy; Gladman, Dafna; Gottlieb, Alice B; Hoepken, Bengt; Bauer, Lars; Irvin-Sellers, Oscar; Khraishi, Majed; Peterson, Luke; Turkiewicz, Anthony; Wollenhaupt, Jürgen; and Mease, Philip, "Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis." (2018). Articles, Abstracts, and Reports. 328.
https://digitalcommons.providence.org/publications/328